<SEC-DOCUMENT>0001213900-19-022028.txt : 20191105
<SEC-HEADER>0001213900-19-022028.hdr.sgml : 20191105
<ACCEPTANCE-DATETIME>20191105114202
ACCESSION NUMBER:		0001213900-19-022028
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20191105
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20191105
DATE AS OF CHANGE:		20191105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Citius Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001506251
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273425913
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38174
		FILM NUMBER:		191192296

	BUSINESS ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016
		BUSINESS PHONE:		(908) 967-6676

	MAIL ADDRESS:	
		STREET 1:		11 COMMERCE DRIVE
		STREET 2:		1ST FLOOR
		CITY:			CRANFORD
		STATE:			NJ
		ZIP:			07016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trail One, Inc.
		DATE OF NAME CHANGE:	20110314

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrailOne, Inc.
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k110519_citiuspharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported)
<U>November 5, 2019</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Citius Pharmaceuticals, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Nevada</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of incorporation)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 49%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">333-206903</FONT></TD>
    <TD STYLE="text-align: center; width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 49%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">27-3425913</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">11 Commerce Drive, 1st Floor, Cranford, NJ</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">07016</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant's telephone number, including area code <U>(908) 967-6677 </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: left">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: left">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: left">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD STYLE="text-align: left">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -13.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -13.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">Securities registered pursuant
to Section 12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 44%; border-bottom: Black 1.5pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Title of each class</P></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 22%; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: Black 1.5pt solid; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">Name of each exchange</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">on which registered</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"></FONT>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Common stock, $0.001 par value</P>



<FONT STYLE="font-size: 10pt"></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">CTXR</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Capital Market</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Warrants to purchase common stock</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">CTXRW</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Capital Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font-family: Wingdings"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font-family: Wingdings"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0"><FONT STYLE="font-family: Wingdings"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item 8.01.</B></FONT></TD>
    <TD STYLE="width: 80%; font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Other Events.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">On November 5, 2019, we mailed to our shareholders and made
available to the investing public a corporate update on our company. A copy of the corporate update is attached as Exhibit 99.1
to this Current Report on Form 8-K and is incorporated by reference herein.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="width: 80%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 17%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 81%; border-bottom: black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><A HREF="f8k110519ex99-1_citius.htm" STYLE="-sec-extract: exhibit">Citius Corporate Update, November <FONT STYLE="font-size: 10pt">2019.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt"><B>CITIUS PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; text-align: left">
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Date: </FONT> <FONT STYLE="font-size: 10pt">November 5, 2019</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Myron Holubiak</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Myron Holubiak</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f8k110519ex99-1_citius.htm
<DESCRIPTION>CITIUS CORPORATE UPDATE, NOVEMBER 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; border-bottom: rgb(51,103,124) 1.5pt solid; padding-bottom: 4pt"><img src="image_004.jpg"></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Citius Corporate Update</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">November 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dear Investors:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Citius Pharmaceuticals, Inc. (&ldquo;Company&rdquo;)
has had a very productive and encouraging quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On September 27, 2019, we closed a $7 million capital raise with H.C. Wainwright (&ldquo;HCW&rdquo;) to position our Company better for growth and advance our ongoing research. We have worked with HCW in the past, and, to date, management has invested nearly $27 million in the Company. This significant investment, when compared to many other biotech micro-cap companies, is a testimony to the commitment we have made to the success of the company and the unwavering belief we share in the potential and value of the assets we are developing. </FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="text-align: right; font-size: 10pt; width: 12%"><IMG SRC="image_001.jpg" ALT=""></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are currently advancing three proprietary
product candidates into large markets that are underserved by the current standards of care:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Mino-Lok&reg;</B>, which is in FDA
Phase III trials, is our lead product and is an antibiotic lock solution for use to treat cancer patients or hemodialysis patients
with catheter-related bloodstream infections (&ldquo;CRBSIs&rdquo;). In a previous Phase IIb trial, Mino-Lok demonstrated a 100%
efficacy rate in salvaging colonized central venous catheters (&ldquo;CVCs&rdquo;) and had no significant adverse events (&ldquo;SAE&rdquo;)
vs. an 18% SAE rate when infected CVCs were removed and replaced.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Mino-Wrap&trade;</B> (or CITI-101),
which is pre-clinical, is a bio-absorbable film impregnated with minocycline and rifampin used to prevent post-surgical infections
and reduce microbial colonization of breast tissue expanders used in breast reconstruction following mastectomies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Halo-Lido</B> (or CITI-002), which
is in FDA Phase II trials, is being developed for symptomatic relief of hemorrhoids and combines the high-potency steroid halobetasol
with lidocaine. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Mino-Lok&reg; (FDA Phase III)
&mdash; Very Positive Progress, Reached the Interim Analysis, Change in End Point, Substantial Savings in Clinical Trial Costs</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following a series of discussions with
the FDA regarding the Mino-Lok trial, we recently announced a change in the pivotal study&rsquo;s primary endpoint to the agreed-upon
&ldquo;time to catheter failure.&rdquo; This change in study design substantially reduced the required sample size of the trial
from 700 subjects to approximately 144 evaluable subjects to achieve the pre-specified 92 catheter failure events needed to conclude
the trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Citius Pharmaceuticals, Inc.</TD>
    <TD STYLE="width: 50%; text-align: right">Tel: (908) 967-6677</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>11 Commerce Drive, First Floor</TD>
    <TD STYLE="text-align: right">Email:&nbsp;&nbsp;info@citiuspharma.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Cranford, NJ 07016</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; border-bottom: rgb(51,103,124) 1.5pt solid; padding-bottom: 4pt"><img src="image_004.jpg"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">It is believed that the median time to
catheter failure for the antibiotic lock therapy (&ldquo;ALT&rdquo;) arm, or the control arm in the trial, is estimated to be 21
days, based on our evaluation of the applicable published studies. The median time to catheter failure for the Mino-Lok therapy
(&ldquo;MLT&rdquo;) arm is expected to be greater than 38 days. Allowing these subjects to keep the catheter for 21 days or longer
is clinically meaningful, as it eliminates the need for patients to undergo often painful removal and replacement procedures of
CVCs. Replacement procedures of CVCs are inherently costly and risky, given the typically high-risk patient population being treated.
Importantly, patients would have continuous venous access for therapy for their underlying disease, and this would represent a
major step forward in the treatment of CRBSIs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition to the significant reduction
in patients now required to complete the trial, the new trial protocol also incorporates two interim analyses, a futility analysis
and a superiority analysis. We recently announced that we reached the first interim analysis of the trial, the futility analysis.
The trial data is being gathered, analyzed, and sent to our drug monitoring committee (&ldquo;DMC&rdquo;), composed of three independent
experts and an unblinded statistician, for the standard futility analysis. The outcome of the futility analysis is expected by
the end of 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%; text-align: left; font-size: 10pt; vertical-align: top"><IMG SRC="image_002.jpg" ALT=""></TD>
    <TD STYLE="width: 2%; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As we await the futility analysis report,
        we also anticipate closing in on the superior efficacy analysis and expect to reach the required number of catheter failure events
        for this analysis in early 2020. The superior efficacy analysis is designed to determine if there is sufficient statistical evidence
        to justify concluding the trial early due to overwhelming efficacy of Mino-Lok once 69 catheter failure events (75% of the 92 catheter
        failure events designed into the trial) have occurred in the trial. If the trial is not concluded early due to the superiority
        analysis, the trial is expected to conclude by the third quarter of 2020.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regarding Mino-Lok, it is important to
        note that these changes to the trial&rsquo;s protocol could save the Company approximately $10 million in clinical trial expenses
        because far fewer patients than originally anticipated would need to be enrolled. Moreover, the trial should take considerably
        less time due to the lower enrollment requirements, and there is a chance of the trial being concluded even earlier now that there
        is a superiority analysis added to the protocol. While it took some time to get to this point, we are very excited about the regulatory
        path Mino-Lok is now on.</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management is confident that Mino-Lok has
$750+ million/year potential in the U.S. market and at least that in the rest of the world, bringing worldwide market potential
to $1.5+ billion/year. We feel there is tremendous value in the Company&rsquo;s assets and commercial outlook, as witnessed by
our repeated investments in each financing round and our total investment of nearly $27 million to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Citius Pharmaceuticals, Inc.</TD>
    <TD STYLE="width: 50%; text-align: right">Tel: (908) 967-6677</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>11 Commerce Drive, First Floor</TD>
    <TD STYLE="text-align: right">Email:&nbsp;&nbsp;info@citiuspharma.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Cranford, NJ 07016</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; border-bottom: rgb(51,103,124) 1.5pt solid; padding-bottom: 4pt"><img src="image_004.jpg"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Mino-Wrap<SUP>TM </SUP>&mdash;
Post-Mastectomy Infection Prevention, Unmet Need, Jurisdictional Status Determined, Preparations for Pre-IND Meeting</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has expanded its relationship
        with MD Anderson Cancer Center by entering into a worldwide license for Mino-Wrap. Mino-Wrap is a bio-absorbable, antimicrobial
        solid film wrap that would be wrapped around a tissue expander and placed in the surgical pocket following a mastectomy to provide
        prophylaxis against infection for an extended period of time. Once installed, it slowly liquefies in place (<I>in situ)</I> for
        a specified period of time, providing extended protection against infection from the most likely pathogens.</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A tissue expander is a silicone implant
        that serves as a temporary device that is placed within a surgical pocket in the mastectomy space and inflated with saline over
        a period of time to prepare the area for a permanent breast implant. After a few months, the tissue expander is removed, and the
        patient receives either microvascular flap reconstruction or the insertion of a permanent breast implant.</P></TD>
    <TD STYLE="width: 2%; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: right; font-size: 10pt"><IMG SRC="image_003.jpg" ALT=""></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The reported rate of tissue expander-related
infections is between 2.5% and 24%, depending on the extent of surgery, duration of post-operative drainage, and many other factors.
Our own research suggests that the post-mastectomy infection rate is approximately 14% even when following the standard prophylaxis
protocol. Once the tissue expander becomes infected, the patient is hospitalized, and the tissue expander may need to be removed.
These serious infections may lead to a delay in lifesaving chemo-radiation therapy, which can be a devastating consequence for
the patient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Mino-Wrap is designed to allow the temporary
tissue expander to be inflated without any restrictions and to prevent infection and biofilm formation surrounding the tissue expander
over a longer duration than that from the current treatment regimen. Mino-Wrap could also be used with breast implants during reconstruction
following removal of the tissue expander.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conclusions from the pre-clinical work
with Mino-Wrap are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mino-Wrap remains intact for at least
one week after being submerged in a collagenase saline solution at 37&deg;C. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Mino-Wrap is safe and not cytotoxic toward
human fibroblasts. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The active ingredients in Mino-Wrap remain
active after gamma radiation sterilization. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The antibacterial components in Mino-Wrap
are active against the most common bacterial clinical isolates responsible for tissue expander infections for at least 10 days.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Essentially, we believe that Mino-Wrap
has the characteristics necessary for an advance in the protection of human implants from subsequent infection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Citius Pharmaceuticals, Inc.</TD>
    <TD STYLE="width: 50%; text-align: right">Tel: (908) 967-6677</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>11 Commerce Drive, First Floor</TD>
    <TD STYLE="text-align: right">Email:&nbsp;&nbsp;info@citiuspharma.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Cranford, NJ 07016</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; border-bottom: rgb(51,103,124) 1.5pt solid; padding-bottom: 4pt"><img src="image_004.jpg"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In late June 2019, the FDA determined that
Mino-Wrap is considered a drug, not a medical device, due to its perceived antibacterial benefits, and will be reviewed by the
FDA&rsquo;s Center for Drug Evaluation and Research (&ldquo;CDER&rdquo;) division. The Company has begun to prepare for a pre-IND
meeting with the FDA, which we expect to occur in early 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Halo-Lido &mdash; Reformulated,
Vasoconstrictor Assay Completed</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company initiated a program to develop
a topical formulation containing a corticosteroid and topical anesthetic to treat symptoms of hemorrhoids. We initially selected
a combination of hydrocortisone acetate, a low-potency steroid, and lidocaine hydrochloride, a well-characterized topical anesthetic,
as our lead formulation. The Company collected valuable data from the Phase II study to modify and further develop the program.
Specifically, we concluded that, compared to hydrocortisone, a higher potency steroid would contribute higher efficacy in combination
with lidocaine hydrochloride.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We subsequently selected halobetasol propionate,
a highly potent steroid, and have reformulated combinations of lidocaine hydrochloride and halobetasol propionate. Several clinical
formulations were successfully manufactured at a 20-kg scale under Good Manufacturing Practice (&ldquo;GMP&rdquo;) conditions.
Additionally, the specifications and analytical procedures used to release the product and assess stability have been developed
and validated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">After testing various formulations <I>in
vitro</I>, we selected two formulations for an <I>in vivo</I> study in healthy volunteers to assess their vasoconstrictive properties
and compare them to commercially available formulations. Dosing has been completed, and there were no serious adverse events reported
in any tested formulation. We will use the results from this study to select one formulation and expect to initiate an acute toxicology
study by year-end before initiating a planned expanded Phase II study in 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Other Corporate Activities &mdash;
Industry Events and Investor Outreach</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In early October, the Company held an in-person
Scientific Advisory Board (&ldquo;SAB&rdquo;) meeting where we were fortunate to gain strategic insight from our SAB members, who
are leaders in the field of infectious disease. Their guidance will be pivotal as we continue to advance our Mino-Lok Phase III
trial along with plans for the development of Mino-Wrap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In early October, we also held an investigator
meeting where an update on the Mino-Lok&reg; trial was provided to a set of principal investigators and their staff. The consensus
of the attendees confirms the Company&rsquo;s belief that Mino-Lok therapy has the potential to change the standard of care and
would be a welcome addition for the adjunctive treatment of CRBSIs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We continue an aggressive investor outreach
campaign. In the fourth quarter of 2019, we attended or plan on attending the H.C. Wainwright, Dawson James, BioFlorida, and LD
Microcap conferences. Additionally, we often meet with microcap and/or healthcare investors at roadshows and luncheons in a number
of cities, including New York, Boston, Philadelphia, and West Palm Beach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Citius Pharmaceuticals, Inc.</TD>
    <TD STYLE="width: 50%; text-align: right">Tel: (908) 967-6677</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>11 Commerce Drive, First Floor</TD>
    <TD STYLE="text-align: right">Email:&nbsp;&nbsp;info@citiuspharma.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Cranford, NJ 07016</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; border-bottom: rgb(51,103,124) 1.5pt solid; padding-bottom: 4pt"><img src="image_004.jpg"></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>NASDAQ Listing</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt">We recently
disclosed that the Company no longer complies with the $1.00 minimum bid price requirement for continued listing on the Nasdaq
Capital Market. Importantly, this noncompliance has no immediate effect on the listing or trading of the Company&rsquo;s common
stock. We have until April 27, 2020 to regain compliance with the minimum bid price requirement and intend to consider all available
alternatives that would allow for continued listing of the common stock on the Nasdaq</FONT> Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I><U>Moving Forward into Fiscal Year
2020</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Looking ahead, we view our corporate road
map with a renewed sense of confidence. In the coming months, our primary focus will be on Mino-Lok and finalizing the futility
analysis from the pivotal trial, reaching the second interim analysis (testing for the superiority) in the trial, and successfully
concluding the trial. These are key milestones for the Company, and we are quite eager to reach them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management has conviction in our strategy
and assets and has expressed such with our repeated financial commitment to invest tens of millions of dollars alongside our investors.
We are extremely excited about our Mino-Lok pivotal trial, especially now that we are reaching important clinical milestone events.
We believe that we clearly see the light at the end of the tunnel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On behalf of the Citius Pharmaceutical
team, we thank you for your continued support and look forward to developing breakthrough technologies that will significantly
enhance and improve the lives of patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sincerely,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Myron Holubiak</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Executive Officer, President, and
Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Leonard Mazur</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chairman of the Board</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Safe Harbor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>This communication may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs
concerning future events impacting Citius. You can identify these statements by the fact that they use words such as &ldquo;will,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;should,&rdquo; and &ldquo;may,&rdquo; and other
words and terms of similar meaning or use of future dates. Forward-looking statements are based on management&rsquo;s current expectations
and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and
stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks associated
with conducting our Phase 3 trial for Mino-Lok&reg;, including completing patient enrollment, opening study sites, and achieving
the required number of catheter failure events; risks associated with developing Mino-Wrap&trade;, including that preclinical results
may not be predictive of clinical results and our ability to file an IND; the estimated markets for our product candidates and
the acceptance thereof by any market; our need for substantial additional funds; risks related to our growth strategy; our ability
to identify, acquire, close, and integrate product candidates and companies successfully and on a timely basis; risks relating
to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage
of products under development; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships;
our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition;
as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes
in events, conditions, or circumstances on which any such statement is based, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Citius Pharmaceuticals, Inc.</TD>
    <TD STYLE="width: 50%; text-align: right">Tel: (908) 967-6677</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>11 Commerce Drive, First Floor</TD>
    <TD STYLE="text-align: right">Email:&nbsp;&nbsp;info@citiuspharma.com</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Cranford, NJ 07016</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !M , # 2(  A$! Q$!_\0
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M()(VTHM,&!!., 9W #D8XK(FADMYGBE1HI8V*NC@AE(."".QKVO0?"'B#1?
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M )(?_;:/^&8?^IE_\D/_ +;1_:>$_G_!_P"0?4Z_\OXH\+HKW3_AF'_J9?\
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MI87$1=TOQ1X717NG_#,/_4R_^2'_ -MH_P"&8?\ J9?_ "0_^VU7]IX3^?\
M!_Y$_4Z_\OXH\+HKW3_AF'_J9?\ R0_^VT?\,P_]3+_Y(?\ VVC^T\)_/^#_
M ,@^IU_Y?Q1X717NG_#,/_4R_P#DA_\ ;:/^&8?^IE_\D/\ [;1_:>$_G_!_
MY!]3K_R_BCPNMWP'_P CSX=_["-O_P"C5KU?_AF'_J9?_)#_ .VU>T']G7^P
M]<T[4?\ A(/.^QW,=QY?V+;OV,&QGS#C..N*SJ9EA90:4^G9_P"14<)64DW'
$\C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $! , # 2(  A$! Q$!_\0
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M_M%U<?VC=^?=(8[B7SVW3*>JN<Y8>QK;TCP'-J%GXFDN;C['<:''ND@V!][
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MQ7-U-<16Z[(4ED+"-?103P/85J^ _P#D>?#O_81M_P#T:M85;O@/_D>?#O\
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M20VL+7EPT5J2;>-I6*PDG)*#/R\\\5SK /=-)^7^%K\]366)3;TNG?\ -/\
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MCD\\5BQ^)=2CT6/24NF2PCN/M:QJJ@K+C&X-C=T]Z\6G@JD%'5)JRT;Z7O\
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M[=,<8CZ]3M=)M?IIKOY^I?U:=^5M=OG=K]#R&TM9;ZZAMH%WS3.L:+D#+$X
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M7W'KCT^F*X2BE]6HV2Y5H/VU2][G0WOCB_OO^$?\R*W']B*J6^U6^8*01O\
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M]\4:Q<ZGJ$@DN9VR=HPJ@# 4#L ,"M*=.LJSE)Z:]?NTZ6(E.G[.RW]/O?\
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H %%%% !1110 4444 %%%% !1110 5/I__'];?]=%_F***3V&MS__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #0 , # 2(  A$! Q$!_\0
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MO,::YM);=I3M#>6J%20YSPIQGK7-VOAG6+ZXN+>VTF^N)[<[9HHK9V:(\\,
M,CH>OI7N%G?7;?%;QYIEK=R17-U8-]EA68H&G\I-K+S@,!WZ@ U1^'-EXBFT
M_4-'O+>YEWZDWVR^L-5$5[9RA0"SY.)%/;D_=;@\5A'&5(PYI6VB]=-]WT-9
M4(<UE_,U]VQX8RE&*L"K X((Y%)6OXP5$\5:L([T:BGVJ0B[7&)<L3NXX_+C
MTK(KV82YHJ7<X9QY9./8****L@*W? ?_ "//AW_L(V__ *-6L*MWP'_R//AW
M_L(V_P#Z-6LJO\.7HRX?$C"HHIT<;S2+'&K.[$*JJ,DD] !6I VBM&;PWJ]L
MT2S:5>Q-++Y$8>W<%Y/[@R.6]NM3+X9O[/5M/M-4L;S3Q=2J@^T0M$Q4L 2N
MX>]1SQZ,IQ:U:,BBNO\ %GP_O+#Q=JNEZ'8:AJ=K9.B[XX3,PW(&^8HN.Y[=
MJJ^&_A[K7B@ZF+6V:-M/C9Y5FC<$LO6)0%/[S_9.*R6(IN'M+Z6O]Y;I34N2
MVM['-45T$?A7;X=U2_NI;JTO+&9839M8RD$D@'?)C;&1GHW)Q5"X\.:M9Z>M
M]/I=[!9,%*W,ENZQD'H0Q&.>U:*I!]2>678L:]XKN_$.GZ19W,<*1:9!]GA,
M2D%EXY;).3QVQ6-6I;>%=;O%5K?1[^=6C$JF.U=@4.<,,#H<'GIQ4.F:#J>M
M&4:=IUW?F+'F"U@:39G.,[0<=#^5*+IP346DE^H/FE9LHT5V.C^!UU;P'J.J
MQ1WDVK07R6L5K"NX,"!GY=NXGD]#5#P]X0DU+7Y=+U)KO298XFD9?L$L\HP
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M]?3I1]?]Z24=O/S2_4%AM%KOY'@]%7-8UB[U[4I]0OY?/NYSNDDV*NXX Z*
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ME_\ B:/^$#\3?]"[JW_@#+_\31[6G_,OO#DEV,*BMW_A _$W_0NZM_X R_\
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MAECPH;=QC''J#Q7*>+?%U_XSU07U_P"4C+&L,<-NFV.)!T51D\9)/)/6G_\
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M#\3?]"[JW_@#+_\ $T?\('XF_P"A=U;_ , 9?_B:/:T_YE]X<DNQA5N^ _\
MD>?#O_81M_\ T:M'_"!^)O\ H7=6_P# &7_XFMGP5X+\0VOC+09Y]!U.&&._
?MW>22SD5542*222O  [UE5JT_9R]Y;/J7"$N9:'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  C ,$# 2(  A$! Q$!_\0
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MF)KJ;I4H4,.G4DY^SDERIWE:*3<DG_0-17X?_L.?\%>M?^.O[0MW^R#^U/\
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MXO--N;S1;[4]*N)8"Z[I+&_NH"6PLI((')T^?Z'?U^7ZG\K7_!K5_P I8/\
M@M5_V.GBC_UIOXL5:_X,MR$\3_\ !5ZW<A9T^)7P$9HFXD4+J'[1$;$KU #@
MJ3V8$=:^P?\ @WV_X)[?MF?LD?\ !1;_ (*I_&']HWX$>(_A9\-/CEXLU^[^
M$_BS6=9\':C8^-K:\^._Q#\76T^F6_A[Q'K&HPQ2^'M:TW40^HV=D%2X6%]M
MRKPK\,']@K_@M9_P0]_;\_:F^-__  3'_9S\%_MB?LN_M4:YJ^L1^$]0N;/4
MCHNEWGB?6?&'A;P[XM\+6?COX?\ CC1O%OPPU'Q1XAT'1/%&A7&M>%/$WAB^
M>XU);;5;M]-T-[M_A^ EI;R9M^)E:;_@][\,"(&0Q> -/:4)AC&J?\$]M09B
M^/NA592<\@,IZ$5J_MK?\$FO^"OW_!.__@I#^T-_P5+_ ."1EWX>^,NA?'?7
M/&WC3XA?"46^AZIX]M[#XC:YIWC/XC?#[7OAQXIN=*M?B;X.N_'%A!XC\)W/
MP[\0VGQ%T\0V=C::7%=Z6=5UCZ/_ ."+?_!+?_@HGXK_ ."E_P 8O^"RG_!4
M[POX?^%'Q>\8Z#XCTOX:_"33-1T2\UN'6/%7A[3?A\=6N=)\/:[XJL?!7@CP
M/\+=(;P/X2\.ZOXCU/QCJ\FIR:OK_P!C?3Q<^(-'X]_MW?\ !U/\)_C#\>/
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IHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
